Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Https://www.insidermedia.com/news/north-west/genedrive-secures-new-funding-facility
Note the similarity to Sareum’s Facility. Peel Hunt involved in both.
Sad. Very well said. The level of research and discussions of the science has been a key feature on this Board and is why so many investors here held onto their shares thru good and difficult times. Seems it is about to all come together. Well done all.
Lots of blue today. In the past this type of activity was putting us in the 7p range ( equivalent to £3.50) Since then the company has progressed significantly yet the share price is under 2p. This is an amazing bargain with the multiple treatments possible in a range of autoimmune and Cancers. Definitely hold onto your shares at all cost and if you are waiting to buy this is now your moment in my opinion.
Maths prof - the delayed trade was placed 1 minute before the three sells for the same amount of shares. So why did they delay the buy as ‘unknown’ at an obvious buy price whist publishing the three sells straightaway. The MMS are clearly not on our side -manipulation has been going on for some months now. We need to highlight as many examples as possible if only to remind them we (and others) know what’s going on.
Https://bit.ly/47YLMXs
Physiomics has today signed a 125k contract with an unnamed British biotech to support the development of an immune oncology molecule. No mention of the name of the company. Just wondered if it could be related to SD1802. Will soon find out.
And if we ever see SRA 737 in clinic that too would be used in combo to treat many solid tumour Cancers. There are around 20 Solid Tumours and at least half of those have a TP53 mutation which Makes them very vulnerable to chk1 (SRA 737) cell lethality.
Thanks Ahfam. Interesting. If it is based on future earnings as below, Sareum could have multiple applications in Autoimmune and Cancers. And with the advantage of oral delivery it could turn out to be a very expensive takeover?
Agreed Aber. I was a Sierra Oncology shareholder and the shorts ignored the obvious and were wiped out. This led to some winging about the takeover process which never came to anything.
Https://x.com/physiomics/status/1697239274629030376?s=12
I recall Merk being very interested in using SRA737 in Cancer combination therapies.